39204-47-2

Usage

InChI:InChI=1/C5H5ClN2/c6-3-5-4-7-1-2-8-5/h1-2,4H,3H2

Upstream product

• 109-08-0 2-Methylpyrazine 
• 6705-33-5 pyrazin-2-ylmethanol 
• 128-09-6 N-chloro-succinimide 
• 6164-79-0 methyl pyrazine-2-carboxylate 
• 98-97-5 2-pyrazylcarboxylic acid 

Downstream Products

• 126473-96-9 (1-phenyl-3-butynyloxy)methylpyrazine 
• 543697-46-7 2-[(2R,3R,4S,5R,6R)-2-(5-Azido-pentyloxymethyl)-4,5-bis-benzyloxy-6-methoxy-tetrahydro-pyran-3-yloxymethyl]-pyrazine 
• 543697-49-0 3-{2-[(2R,3R,4S,5R,6R)-6-(5-Azido-pentyloxymethyl)-3,4-bis-benzyloxy-5-(pyrazin-2-ylmethoxy)-tetrahydro-pyran-2-yloxy]-ethyl}-1-benzenesulfonyl-1H-indole 
• 543697-28-5 5-[(2R,3R,4S,5R,6R)-6-[2-(1-Benzenesulfonyl-1H-indol-3-yl)-ethoxy]-4,5-bis-benzyloxy-3-(pyrazin-2-ylmethoxy)-tetrahydro-pyran-2-ylmethoxy]-pentylamine 
• 87831-85-4 β-pyrazinyl-L-alanine 
• 126473-99-2 8H-5,6-dihydropyrano<3,4-b>pyridine 
• 126474-04-2 6-Phenyl-5,8-dihydro-6H-pyrano[3,4-b]pyridine 
• 126474-11-1 2-(1-Phenyl-4-trimethylsilanyl-but-3-ynyloxymethyl)-pyrazine 
• 59021-02-2 2-(mercaptomethyl)pyrazine 
• 582303-19-3 diethyl α-(4-tert-butyldimethylsilyloxy-3-methoxy-5-methylphenyl)-β-(2-pyrazinyl)ethylphosphonate 
• 20010-99-5 2-aminomethylpyrazine 
• 1432912-54-3 5-chloro-2-hydroxy-N-(pyrazin-2-ylmethyl)benzamide 
• 1432912-53-2 4-chloro-2-(imidazo[1,5-a]pyrazin-3-yl)phenol 

Relevant academic research and scientific papers

FREE RADICAL CHLORINATION OF METHYL DERIVATIVES OF PYRIDINE, PYRAZINE, AND THIAZOLE BY N-CHLOROSUCCINIMDE

When methylazines (2-, 3-, and 4-methylpyridines, methylpyrazine) are treated with N-chlorosuccinimide they undergo successive chlorination of the methyl group to give 2-chloromethylpyridine, 2-dichloromethylpyridine, and dichloromethylpyrazine in preparative yields. 3-Dichloromethylpyridine was synthesized from pyridine-3-aldehyde and PCl5.The primary chlorination products of 4-methylthiazole are 4-methyl-5-chlorothiazole and 5-chloro-4-chloromethylthiazole.

New strategy for quantifying biological zinc by a modified zinpyr fluorescence sensor

Substitution of one pyridine by pyrazine in each DPA appendage of ZP1 leads to a new zinc sensor, ZPP1, with a modified background fluorescence and zinc affinity. ZPP1 exhibits a two-step zinc response during fluorescence titrations, which leads to a new method for zinc quantification. The ability of ZPP1 to image and quantify zinc was demonstrated in pancreatic Min6 cells. Copyright

Synthesis and characterization of nitrogen-rich macrocyclic ligands and an investigation of their coordination chemistry with lanthanum(III)

Derivatives of the ligand 1,4,7,10-tetraazacyclododecane (cyclen) containing pendant N-heterocyclic donors were prepared. The heterocycles pyridine, pyridazine, pyrimidine, and pyrazine were conjugated to cyclen to give 1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane (Lpy), 1,4,7,10-tetrakis(3-pyridazylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyd), 1,4,7,10-tetrakis(4-pyrimidylmethyl)-1,4,7,10-tetraazacyclododecane (Lpyr), and 1,4,7,10-tetrakis(2-pyrazinylmethyl)-1,4,7,10-tetraazacyclododecane (Lpz), respectively. The coordination chemistry of these ligands was explored using the La3+ ion. Accordingly, complexes of the general formula [La(L)(OTf)](OTf)2, where OTf = trifluoromethanesulfonate and L = Lpy (1), Lpyd (2), Lpyr (3), and Lpz (4), were synthesized and characterized by NMR spectroscopy. Crystal structures of 1 and 2 were also determined by X-ray diffraction studies, which revealed 9-coordinate capped, twisted square-antiprismatic coordination geometries for the central La3+ ion. The conformational dynamics of 1-4 in solution were investigated by variable-temperature NMR spectroscopy. Dynamic line-shape and Eyring analyses enabled the determination of the activation parameters for the interconversion of enantiomeric forms of the complexes. Unexpectedly, the different pendant N-heterocycles of 1-4 give rise to varying values for the enthalpies and entropies of activation for this process. Density functional theory calculations were carried out to investigate the mechanism of this enantiomeric interconversion. Computed activation parameters were consistent with those experimentally determined for 1 but differed somewhat from those of 2-4.

Mononuclear Fe(II) Complexes Based on the Methylpyrazinyl-Diamine Ligand: Chemical-, Thermo- and Photocontrol of Their Magnetic Switchability

Two new mononuclear Fe(II) complexes, [Fe(2MeLpz)(NCX)2] (L = N,N′-dimethyl-N,N′-bis((pyrazin-2-yl)methyl)-1,2-ethanediamine and X = S (1), BH3 (2)), have been synthesized and characterized by single-crystal X-ray diffraction, magnetic, optical reflectivity, and photomagnetic measurements. They have similar FeN6 coordination environments offered by the tetradentate ligand with a cis-α conformation and two NCX- coligands in cis positions. However, 1 and 2 have different molecular arrangements and crystal packings, and are isolated in orthorhombic Pbnb and monoclinic C2/c space groups, respectively. 1 remains in a high spin state (S = 2) over all temperatures while 2 undergoes a spin transition around 168 K with a small thermal hysteresis of about 0.4 K (at a temperature scan rate of 1.3 K min-1). This phase transition, which can also be optically detected due to the associated marked change of the sample color, occurs between two structurally characterized phases, which exhibit Fe(II) complexes in their high spin and low spin states at high and low temperatures, respectively. The reversible photoswitching between these two states has also been confirmed at low temperatures using well separated wavelength irradiations.

Hederagenin compound H-X with anti-lung cancer effect and preparation method and application thereof

The invention provides a hederagenin compound H-X with an anti-tumor effect and a preparation method and application thereof. The structural general formula 1 is shown in the specifications. Most of the derivatives provided by the invention have obvious inhibition effects on tumor cells A549, MCF-7 and HepG2, and the compound hederagenin-2, 6-dimethylpyrazine (H-08) shows good selectivity betweentumors and normal conditions, especially on lung cancer A549 cells. The IC50 of the compound to A549, MCF-7, HepG2, MDCK and H9c2 is 3.45+/-0.59 muM, 8.73+/-1.49 muM, 8.71+/-0.38 muM, 14.11+/-0.04 muM, and 16.69+/-0.12 muM, the inhibition effect on A549 cells is similar to that of a positive drug cis-platinum (IC50 is 3.85+/-0.63 muM), but the toxicity on MDCK and H9c2 is obviously lower than thatof cis-platinum.

Monoacylglycerol Lipase Modulators

Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.

NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS

The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

Design, synthesis, and cytotoxic analysis of novel hederagenin–pyrazine derivatives based on partial least squares discriminant analysis

Hederagenin (He) is a novel triterpene template for the development of new antitumor compounds. In this study, 26 new He–pyrazine derivatives were synthetized in an attempt to develop potent antitumor agents; they were screened for in vitro cytotoxicity against tumor and non-tumor cell lines. The majority of these derivatives showed much stronger cytotoxic activity than He. Remarkably, the most potent was compound 9 (half maximal inhibitory concentration (IC50) was 3.45 ± 0.59 μM), which exhibited similar antitumor activities against A549 (human non-small-cell lung cancer) as the positive drug cisplatin (DDP; IC50 was 3.85 ± 0.63 μM), while it showed lower cytotoxicity on H9c2 (murine heart myoblast; IC50 was 16.69 ± 0.12 μM) cell lines. Compound 9 could induce the early apoptosis and evoke cell-cycle arrest at the synthesis (S) phase of A549 cells. Impressively, we innovatively introduced the method of cluster analysis modeled as partial least squares discriminant analysis (PLS-DA) into the structure–activity relationship (SAR) evaluation, and SAR confirmed that pyrazine had a profound effect on the antitumor activity of He. The present studies highlight the importance of pyrazine derivatives of He in the discovery and development of novel antitumor agents.

SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted 1 H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

Preparation method of medical intermediate N-(2-methylpyrazine)benzylamine phosphate compound

The invention discloses a preparation method of a medical intermediate N-(2-methylpyrazine)benzylamine phosphate compound. The method includes the steps of: under the protection of nitrogen, adding 2-methylpyrazine, dibenzoyl peroxide and N-chlorosuccinimide in a mole ratio of 1:0.05-0.1:1-1.4 into a solvent anhydrous carbon tetrachloride, and carrying out reflux reaction to obtain alpha-chloromethyl pyrazine; adding benzylamine and cesium hydroxide in a mole ratio of 1:1-1.3 into a solvent anhydrous dimethylformamide, under stirring, adding alpha-chloromethyl pyrazine according to a alpha-chloromethyl pyrazine/benzylamine mole ratio of 1:1-1.3, thus obtaining N-(2-methylpyrazine)benzylamine phosphate with a content of 95-97%; and subjecting the N-(2-methylpyrazine)benzylamine phosphate to recrystallization in methanol-chloroform, thus obtaining a N-(2-methylpyrazine)benzylamine phosphate product with a content of more than 99.5%. The method has the advantages of easily available raw materials, high total yield, and simple post-treatment.